The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
% SDS-PAGE. >90% by SDS-PAGE analyses.
Reconstituted VEGFC should be stored in working aliquots at -80°C.
Concentration information loading...
Shipped at 4°C. Upon delivery aliquot. Store at -80°C. Avoid freeze / thaw cycle.
Constituents: 0.1% Acetic acid, with 50 µg BSA per 1 µg VEGFC.
Endotoxin level is <0.1 ng per µg of VEGFC
We recommend a quick spin followed by reconstitution in 0.1% acetic acid to a concentration of 0.1-1.0 mg/ml.
FLT4 ligand DHM
Vascular endothelial growth factor C
Vascular endothelial growth factor related protein
Vascular endothelial growth factor-related protein
Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.
Spleen, lymph node, thymus, appendix, bone marrow, heart, placenta, ovary, skeletal muscle, prostate, testis, colon and small intestine and fetal liver, lung and kidney, but not in peripheral blood lymphocyte.
Belongs to the PDGF/VEGF growth factor family.
Undergoes a complex proteolytic maturation which generates a variety of processed secreted forms with increased activity toward VEGFR-3, but only the fully processed form could activate VEGFR-2. VEGF-C first form an antiparallel homodimer linked by disulfide bonds. Before secretion, a cleavage occurs between Arg-227 and Ser-228 producing an heterotetramer. The next extracellular step of the processing removes the N-terminal propeptide. Finally the mature VEGF-C is composed mostly of two VEGF homology domains (VHDs) bound by non-covalent interactions.
Nayar S et al. Bimodal Expansion of the Lymphatic Vessels Is Regulated by the Sequential Expression of IL-7 and Lymphotoxin a1ß2 in Newly Formed Tertiary Lymphoid Structures. J Immunol197:1957-67 (2016).
Read more (PubMed: 27474071) »